Haematological Cancer Survivors

Uses

How it works

Risks & contraindications

Background

Where it comes from

Highlighted claims

• Haematological malignancies include leukaemia, lymphoma, multiple myeloma, and other blood cancers. — Long-term infection risks in haematological cancer survivors compared with individuals with no cancer history: protocol for a systematic review aided by artificial intelligence-based methods
• The review focuses on long-term infection incidence and mortality among haematological cancer survivors compared with people without cancer history or the general population. — Long-term infection risks in haematological cancer survivors compared with individuals with no cancer history: protocol for a systematic review aided by artificial intelligence-based methods
• Haematological cancers and their treatments make infection risk biologically plausible because cancers can impair immunity and treatments are often immunosuppressive. — Long-term infection risks in haematological cancer survivors compared with individuals with no cancer history: protocol for a systematic review aided by artificial intelligence-based methods
• The population living with and beyond haematological cancer is increasing because incidence and survival have risen. — Long-term infection risks in haematological cancer survivors compared with individuals with no cancer history: protocol for a systematic review aided by artificial intelligence-based methods
• Grouping haematological cancers together can hide subtype-specific infection risks. — Long-term infection risks in haematological cancer survivors compared with individuals with no cancer history: protocol for a systematic review aided by artificial intelligence-based methods